Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lenalidomide combined with azacitidine in intermediate-2 or high-risk MDS and AML with del(5q)
2009-011160-11Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Jul 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Started Jul 2009; status: completed.
02
Drugs
lenalidomideazacitidine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-011160-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011160-11.